Unicycive Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4300 El Camino Real Ste 210, Los Altos, ...Phone Number
(650) 351-4495Website
www.unicycive.comRevenue
-Stock Symbol
UNCYIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Unicycive Therapeutics
Unicycive is a biotechnology company developing novel treatments across multiple therapeutic areas, currently focusing on kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.Explore more
Unicycive Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Unicycive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Unicycive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Unicycive Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Unicycive Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Unicycive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Unicycive Therapeutics recently announced quarterly report
Check out if Unicycive Therapeutics is spiking on competitors!
Product Launch: Get notified when Unicycive Therapeutics launches new products
Funding: Get notified immidiatlly once Unicycive Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Unicycive Therapeutics
Find 2 more new buyers
Compare Similar Companies to Unicycive Therapeutics
Compare insights from companies similar to Unicycive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Unicycive Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Unicycive Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Unicycive Therapeutics.
Unicycive Therapeutics financials insights
Gather financial insights about Unicycive Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$130M
2025
Stock/Share Issuance
$16.3M
Unicycive Therapeutics Tech Stack
A closer look at the technologies used by Unicycive Therapeutics
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Project
Unicycive Therapeutics has reported that clinical stage biotechnology company focused on treatment for kidney diseases, has developed oxylanthanum carbonate as its lead drug candidate, which is pending FDA review for hyperphosphatemia in patients with chronic kidney disease.
Product Development, Pharmaceuticals, Clinical Operations
Hiring Plans
Unicycive Therapeutics has reported that the company already has a VP of sales on board and plans to hire additional leadership team members including a field reimbursement manager and market access team members.
Hiring Plans, Sales, HR Operations, Talent Acquisition
Project
Pharmaceuticals, Manufacturing Operations, Operations
Unicycive Therapeutics News & Media
ROSEN, A LEADING NATIONAL FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY
NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline.Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026UNCY DEADLINE: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. Investors of Upcoming Securities Class Action Deadline
A securities class action alleges Unicycive Therapeutics told shareholders its oxylanthanum carbonate application was on track without ever inspecting its third-party manufacturer's facility for cGMP compliance. UNCY purchasers who lost $3.01 per share have specific rights under the...UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
A securities class action alleges Unicycive Therapeutics leaned on a contract manufacturer already cited by the FDA for cGMP deficiencies, without verifying the vendor's compliance status, before the same deficiencies triggered a second Complete Response Letter and a 39.1% single-day collapse in UNCY shares. A securities class action alleges Unicycive Therapeutics leaned on a contract manufacturer already cited by the FDA for cGMP deficiencies, without verifying the vendor's compliance status, b
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Unicycive Therapeutics
Sign Up For FreeTo access detailed company insights
Unicycive is a biotechnology company developing novel treatments across multiple therapeutic areas, currently focusing on kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with issued composition of ma... Read More
